Added to YB: 2025-08-12
Pitch date: 2025-08-10
GILD [neutral]
Gilead Sciences, Inc.
+1.68%
current return
Author Info
Disruptive Analytics has 30+ years of experience as a retail investor and is now fully engaged in managing their own money. Sign up for the newsletter.
Company Info
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally.
Market Cap
$149.4B
Pitch Price
$117.63
Price Target
125.00 (+4%)
Dividend
2.62%
EV/EBITDA
11.45
P/E
18.75
EV/Sales
5.63
Sector
Biotechnology
Category
growth
Great Results! Gilead Sciences, Inc.
GILD (earnings update): Up 65% in 2024, now near $120. Q2 showed 4% YoY revenue growth to $7.1B, HIV sales +7% to $5.1B. New Yeztugo (twice-yearly PrEP) generated $107M in first quarter, expected to reach $5B by 2030. JP Morgan PT $135. Cell therapy -7%, Veklury -44%. My fair value raised from $115 to $125.
Read full article (2 min)